Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02014116 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02014116 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 51 participants.
The verdict
NCT02014116, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
Interventions
- DRUG LY3009120 capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-11-26 |
| Est. Completion | 2018-10-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02014116
The ClinicalTrials.gov registry entry for NCT02014116 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3009120 capsule is the first listed.
NCT02014116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02014116 about?
NCT02014116 is a clinical study titled "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body". The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
What is the current status of trial NCT02014116?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2013-11-26. Estimated completion is 2018-10-05.
What interventions are being tested in trial NCT02014116?
The interventions under investigation include: LY3009120 capsule (DRUG).
Who is sponsoring clinical trial NCT02014116?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.